Use of lysozyme-c-specific antibody in preparation of drug for treating liver cancer

Abstract

Disclosed in the present disclosure is the use of a lysozyme C-specific antibody in the preparation of a drug for treating liver cancer, which belongs to the field of medical formulations. The technical problem to be solved by the present application is how to provide a new therapeutic option and basis for hepatocellular carcinoma. In order to solve the technical problem, provided in the present application is the use of a lysozyme C-specific antibody in the preparation of a drug for treating and/or preventing liver cancer. The drug inhibits the proliferation and migration of liver cancer cells and inhibits the growth of hepatic malignant tumors, and the lysozyme C-specific antibody is a monoclonal antibody or polyclonal antibody against lysozyme C. In the study, the effect of the lysozyme C-specific antibody in the treatment of hepatocellular carcinoma is evaluated independently from different angles in vivo and in vitro, so as to provide a new option and basis for the treatment of malignant hepatocellular carcinoma.

Dependencies are inferred from the claim text.